Follow us on Twitter
This page is updated frequently with new Antagonist-related patent applications. Subscribe to the Antagonist RSS feed to automatically get the update: related Antagonist RSS feeds. RSS updates for this page: Antagonist RSS
|| List of recent Antagonist-related patents
| Antagonists of il17c for the treatment of inflammatory disorders|
The present invention provides antagonists of il17c for use in the treatment of an inflammatory disorder.. .
| Piperidinyl alkyne orexin receptor antagonists|
The present invention is directed to piperidinyl alkyne compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the piperidinyl alkyne compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
| Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists|
The invention is related to methods of preventing and treating hepatic fibrosis using a2b adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method..
| Drug for the treatment of allergic rhinitis comprising pgd2 antagonist and histamine antagonist|
A medicament for treating allergic rhinitis, characterized in that (a) a compound represented by the formula (i) or a pharmaceutically acceptable salt thereof, is combined with (b) at least one compound selected from the group consisting of cetirizine, fexofenadine, and loratadine, or a pharmaceutically acceptable salt thereof. Since the effects of the medicament for treating allergic rhinitis of the present invention surpass the sum of the effects of single dose of each of the agents against the allergic rhinitis, the medicament is useful as a medicament for treating allergic rhinitis having potent effects..
| Polynucleotides encoding signal peptide-containing molecules|
The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
| Combination therapy for the treatment of ocular neovascular disorders|
The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a pdgf antagonist and a vegf antagonist to the patient. The invention also features a pharmaceutical composition containing a pdgf antagonist and a vegf antagonist for the treatment or prevention of a neovascular disorder..
| Methods and compositions for delivering interleukin-1 receptor antagonist|
Methods and compositions generating and using an interleukin-1 receptor antagonist (il-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating adipose tissue and/or adipocytes with polyacrylamide beads to produce interleukin-1 receptor antagonist.
Wherein r1, r2, r3, r4, r5, r6, r7, w, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma..
|Fibroblasts cellular model for assessing efficacy of cancer treatments by shh/ptch pathway antagonists|
A cellular model is described that targets dysregulation or inappropriate activation of the sonic hedgehog/patched (shh/ptch) pathway. Also described, is a screening method using this cellular model to screen for pharmacological compounds that can treat or prevent skin cancer, in particular, basal cell carcinoma, (bcc) lesions..
|Food products, preparation, and therapeutic methods|
A method is provided for the supplementation of milk, dairy products, meat products, and other food substances generally considered to be a major part of the western diet, with substances capable of balancing the ratio of methionine and cysteine. Drug therapy with various carbamoyl thioesters or glutamate receptor antagonists can also be used, alone or in combination with dietary supplements and vitamins, to prevent or treat the pathology resulting from a western diet..
|Combination therapy for glaucoma|
Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: β-blockers, adrenergic agonists, non-selective adrenergic agonists, α2-selective adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, glutamate antagonists, ca2+ channel blockers, prostamides, prostaglandins, cannabinoids, and combinations thereof. Compositions and medicaments containing a combination of these two active agents are also disclosed..
|New ccr2 receptor antagonists and uses thereof|
The present invention relates to novel antagonists for ccr2 (cc chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and copd.. .
|Compounds and compositions as selective estrogen receptor degraders|
In which n, m, x, y1, r1, r2, r3, r4 and r5 are defined in the summary of the invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity..
|Trpm8 antagonists and their use in treatments|
Where the definitions of the variables are provided herein.. .
Wherein r1 is 2-indanyl, r2 is 1-methylpropyl, r3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, r4 represents methyl and r5 represents hydrogen or methyl or, r4 and r5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.. .
Wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human s1p2 antagonistic activity. The compound may therefore be used as a therapeutic agent for s1p2-mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases..
|Compositions and methods for suppressing endometrial proliferation|
The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (serm) therapy.
|Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists|
The present invention relates to compounds of formula (i), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are iglur receptor inhibitors, and hence are useful in the treatment of psychiatric diseases or neurological disorders or a disease or disorder associated with abnormal activities of iglur receptors.. .
|Methods for treating neural cell swelling|
A composition comprising a novel ca2+-activated, [atp]i-sensitive nonspecific cation (ncca-atp) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [ca]i.
|Glycoproteins having lipid mobilizing properties and therapeutic uses thereof|
The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
|Ligands modified by circular permutation as agonists and antagonists|
The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof..
|Controlled platelet activation to monitor therapy of adp antagonists|
A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or gpiib/iiia blockade. A blood sample is obtained from the individual being assessed.
|Il-17 receptor a is required for il-17c biology|
The present invention relates to interleukin-17 ligand and receptor family members and the discovery that il-17 receptor a and il-17 receptor e form a heteromeric receptor complex that is biologically active, and that il-17c activity requires the il-17ra-il-17re heteromeric receptor complex. Antagonists of the il-17ra-il-17re heteromeric receptor complex are disclosed, as well as various methods of use..
|Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury|
Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal.
|Inhibition of tumor metastasis|
The invention provides nrp2 antagonists, such as anti-nrp2 antibodies, and their use in the prevention and treatment of tumor metastasis.. .
|Modulation of pilr to treat immune disorders|
The present invention provides methods of using pilrα agonists, or pilrβ antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including cns, joint and gut inflammation.. .
|Therapies for chronic renal failure using one or more integrin antagonists|
The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain integrin antagonists..
|Thienopyrimidinone derivatives as mglur1 antagonists|
Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as parkinson's disease and alzheimer's disease.
|Novel compounds modulating the hedgehog protein signaling pathway, marked forms thereof, and applications|
The invention relates to compounds of formula (i), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (i).
|Combinations of alpha 7 nicotinic acetylcholine receptor activators and mglur5 antagonists for use in dopamine induced dyskinesia in parkinson's disease|
The present invention relates to novel combinations suitable for the treatment of dyskinesia associated with dopamine agonist therapy in parkinson's disease, which comprise, as active ingredients, at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator and at least one low molecular weight metabotropic glutamate receptor 5 antagonist; to their preparation; to their use as medicaments and to medicaments comprising them.. .
|N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists|
The invention provides novel substituted cyclopropane carboxamide compounds according to formula (i), their manufacture and use for the treatment of proliferative or inflammatory diseases, such as cancer, fibrosis or arthritis.. .
A compound represented by formula (ia) or a pharmaceutically acceptable salt thereof, which acts relying on an orexin (ox) receptor antagonistic activity and is useful for the treatment or prevention of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, head ache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases and hypertension.. .
|Method of treatment or prophylaxis|
The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin ii receptor 2 (at2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects.
|Compounds and methods of treating diabetes|
Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor α2a.
Combinations suitable for agricultural use can include (i) a nematode-antagonistic biocontrol agent and (ii) one or more agents selected, independently of each other, from any one of (a) to (h): (a) at least one fungicide; (b) at least one insecticide; (c) at least one synthetic nematicide; (d) bacterium of the genus bacillus; (e) harpin; (f) isoflavones; (g) plant growth regulators; and/or (h) plant activators.. .
|G protein coupled receptor agonists and antagonists and methods of activating and inhibiting g protein coupled receptors using the same|
The invention relates generally to g protein coupled receptors and in particular to agonists and antagonists of g protein receptors and methods of using the same.. .
|Antibodies to human signal peptide-containing proteins|
The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
|Nogo receptor antagonists|
Disclosed are immunogenic nogo receptor-1 polypeptides, nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are nogo receptor antagonist polynucleotides.
|Pd-1 antagonists and methods for treating infectious disease|
Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid t cell mediated responses, (2) induction of t cell exhaustion, t cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other apcs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired t cell inhibition by binding to and blocking pd-1 to prevent or reduce inhibitory signal transduction, or by binding to ligands of pd-1 such as pd-l1, thereby preventing (in whole or in part) the ligand from binding to pd-1 to deliver an inhibitory signal.
|Humanized anti-cmet antagonists|
The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.. .
|Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof|
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase i (alk1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of bmp9 and/or bmp10, ligands for alk1, may also be used to inhibit angiogenesis in vivo..
|Methods and monitoring of treatment with a dll4 antagonist|
Methods for treating diseases such as cancer comprising administering a dll4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.. .
|Systems and methods for local drug delivery to kidneys|
Drug-delivery systems for local drug delivery to kidneys and associated systems and methods are disclosed herein. One aspect of the present technology is directed to drug-delivery systems that include a physiological sensor, an implantable medical device, and a control module configured to communicate with the physiological sensor and to control delivery of a drug in response to a physiological parameter measured by the physiological sensor.
|Deuterated 2-amino-3-hydroxypropanoic acid derivatives|
This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an nmda glycine-site antagonist..
|Arylsulfonamide ccr3 antagonists|
Provided herein are arylsulfonamides that are useful for modulating ccr3 activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a ccr3-mediated disorder, disease, or condition..
|Ccr5 antagonists for treating hiv|
Compounds that modulate the ccr5 chemokine receptor, pharmaceutical compositions containing them, and uses therefor in the treatment of hiv and related diseases are described.. .
|Method of treating dyskinesia|
Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action mu-opioid receptor antagonist/kappa-opioid receptor agonist or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a mu-opioid receptor antagonist or prodrug thereof, and a kappa-opioid receptor agonist or prodrug thereof can be administered, either together or separately..
|Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives|
The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described..
|Thienopyrimidine compounds and use thereof|
Wherein r1 is a c1-4 alkyl; r2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a hydroxy group, (3′) a c1-4 alkyl and (4′) a c1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a c1-4 alkoxy-c1-4 alkyl, (3′) a mono-c1-4 alkyl-carbamoyl-c1-4 alkyl, (4′) a c1-4 alkoxy and (5′) a mono-c1-4 alkylcarbamoyl-c1-4 alkoxy, or the like; r3 is a c1-4 alkyl; r4 is a c1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.. .
|Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists|
The present invention provides 4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior..
|Herbicidal composition comprising polymeric microparticles containing a herbicide|
The invention provides a herbicidal composition comprising a mixture of: (a) polymeric microparticles containing a first herbicide, wherein the first herbicide is a synthetic auxin herbicide (e.g. Dicamba, mcpa or 2,4-d) or an acetolactate synthase (als) inhibitor herbicide (e.g.
|Method of treating pathologic heterotopic ossification|
What is described is a method of preventing or treating heterotopic ossification, vascular calcification, and pathologic mineralization, comprising administering an drug, wherein the drug is an antagonist of the hedgehog (hh) pathway. For example the antagonist consists of arsenic trioxide, sodium arsenite, phenylarsine, gant-58, gant-61, zerumbone vismodegib (gdc-0449, genentech), bevacizumab, gemcitabine, nab-paclitaxel, folfir, folfox, ro4929097, cixutumumab, cisplatin, etoposide, ldac, decitabine, daunorubicin, cytarabin, rosiglitazone, goserelin, leuprolide, capecitabine, fluorouracil, leucovorin, oxaliplatin, irinotecan, diclofenac, bms-833923 (xl139), ipi-926—infinity pharmaceuticals, inc., lde225, leq506—novartis pharmaceuticals, tak-441 millennium pharmaceuticals, inc., and pf-04449913—pfizer, alone or in combination therapy.
|Use of opioid antagonists for treating urinary retention|
The invention pertains to the use of opiod antagonists for the treatment of urinary retention.. .
|Use of cgrp antagonist compounds for treatment of psoriasis|
The invention provides methods and compositions for treating, preventing and/or remedying psoriasis, based on compounds that have a calcitonin-related gene peptide (cgrp) antagonistic effect. Methods are also disclosed for identifying compounds with cgrp antagonist activity which thereby are suitable candidate compounds for treating psoriasis..
|1d05 pcsk9 antagonists|
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“pcsk9”) are disclosed. The disclosed antagonists are effective in the inhibition of pcsk9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with pcsk9 activity.
|Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease|
The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the production of pthrp, its isoforms or pthrp signalling. The present invention is also directed to methods of inhibiting the pthrp1-173 isoform through antagonists thereof, including monoclonal antibodies and sirna directed there against.
|Combinations of modalities for the treatment of diabetes|
A method of treating, preventing, or delaying the progression of type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a t-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic t-lymphocyte-associated antigen 4 (ctla4) molecule and a type 1 diabetes autoantigen.
|Levels of bcma protein expression on b cells and use in diagnostic methods|
The present invention provides a method of measuring the levels of bcma in a biological sample, specifically upon the b cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as sle, and for methods for treating an individual clinically diagnosed with an autoimmune disease.
|Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders|
The present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig), preferably also containing a flexible linker intervening the vista and ig fc polypeptide. The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes..
|Methods and monitoring of treatment with a dll4 antagonist|
Methods for treating diseases such as cancer comprising administering a dll4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.. .
|Method for treatment of chronic neuropathic pain|
Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as d-cycloserine or a glyt-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may also contain a secondary analgesic such as opiates, nsaids or cox-2 inhibitors.
|Methods for treating eye disorders using opioid receptor antagonists|
The present invention discloses methods for treating eye disorders using opioid receptor antagonists. The methods include the step of administering an effective amount of a topically-administered opioid receptor antagonist in the absence of moxifloxacin.
|Lysophosphatidic acid receptor antagonists|
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.. .
|Beta-hairpin peptidomimetics as cxc4 antagonists|
β-hairpin peptidomimetics of the general formula cyclo(-tyr1-his2-xaa3-cys4-ser5-ala6-xaa7-xaa8-arg9-tyr10-cys11-tyr12-xaa13-xaa14-dpro15-pro16-), disulfide bond between cys4 and cys11, and pharmaceutically acceptable salts thereof, with xaa3, xaa7, xaa8, xaa13 and xaa14 being amino acid residues of certain types which are defined in the description and the claims, have favorable pharmacological properties and can be used for preventing hiv infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from cxcr4 receptor activity; or where immunological diseases are mediated or resulting from cxcr4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy..
|Methods for use with baff antagonists|
Baff plays a central role in acquired immunity. The disclosure identifies baff responsive genes that are substantially upregulated by administration of baff and substantially downregulated by treatment with a baff antagonist.
|Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures|
Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures.
The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens.
|Toll-like receptor 3 antagonists|
Toll like receptor 3 (tlr3) antibody antagonists, polynucleotides encoding tlr3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.. .
|Soluble tumor necrosis factor receptor treatment of medical disorders|
The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of tnfα by administering a tnfα antagonist, such as recombinant tnfr:fc.. .
|Use of il-33 antagonists to treat fibrotic disease|
Methods for treating fibrotic disease, such as idiopathic pulmonary fibrosis and scleroderma, with antagonists of il-33 are disclosed.. .
Popular terms: [SEARCH]
Antagonist topics: Antagonist, Recurrence, Proliferative Disorder, Proliferative, Antibodies, Progesterone, Dicyclomine, Scopolamine, Extracellular, Pharmaceutically Acceptable Salt, Metalloprotein, Nucleic Acids, Polynucleotide, Nucleic Acid, Monoclonal
Follow us on Twitter
This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.